In Europe, advanced therapy medicinal products\ud
(ATMPs), including cell and gene medicinal products\ud
, tissue-engineered products and combined\ud
ATMPs, are governed by Directive 2001/\ud
83/EC and Regulation 726/2004, amended by\ud
Regulation 1394/2007, which sets specific rules\ud
concerning their centralized marketing authorization\ud
(MA), supervision and pharmacovigilance.\ud
Nevertheless, ATMPs not intended to be marketed\ud
and not industrially prepared are beyond the scope of\ud
Directive 2001/83/EC, according to article 28 of\ud
Regulation 1394/2007. This is commonly called “hospital\ud
exemption” (HE) and is restricted to any ATMP\ud
“which is prepared on a non-routine basis according to\ud
specific quality standards, and used within the same\ud
Member State in a hospital under the exclusive professional\ud
responsibility of amedical practitioner, in order to\ud
comply with an individual medical prescription for a\ud
custom-made product for an individual patient.”\ud
Member States must ensure that the manufacture of\ud
ATMPs under HE is authorized by the competent national\ud
authority and that traceability, pharmacovigilance\ud
and specific quality standards are equivalent to those\ud
applying to ATMPs granted centralized MA
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.